Favipiravir (Norwegian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Favipiravir" in Norwegian language version.

refsWebsite

Global rank Norwegian rank

13doi.org

2^nd place

9^th place

11nih.gov

4^th place

23^rd place

2reuters.com

49^th place

132^nd place

1fiercepharma.com

low place

1allafrica.com

1,467^th place

1,583^rd place

1croiconference.org

low place

1nytimes.com

7^th place

33^rd place

1sciencemag.org

857^th place

279^th place

1web.archive.org

1^st place

1drugs.com

399^th place

2,066^th place

1livemint.com

390^th place

8,952^nd place

1tass.ru

260^th place

2,248^th place

1legemiddelverket.no

low place

1,694^th place

allafrica.com

«Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea». AllAfrica – All the Time. Besøkt 28. desember 2014.

croiconference.org

«Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea». CROIconference.org. Besøkt 17. mars 2016.

doi.org

«Favipiravir, an anti-influenza drug against life-threatening RNA virus infections». Pharmacology & Therapeutics: 107512. Februar 2020. PMC 7102570 . PMID 32097670. doi:10.1016/j.pharmthera.2020.107512.
«The 2014 Ebola virus disease outbreak in West Africa». The Journal of General Virology. 95 (Pt 8): 1619–1624. August 2014. PMID 24795448. doi:10.1099/vir.0.067199-0.
«Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model». Antiviral Research. 105: 17–21. Mai 2014. PMID 24583123. doi:10.1016/j.antiviral.2014.02.014.
«Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model». Antiviral Research. 104: 153–5. April 2014. PMID 24462697. doi:10.1016/j.antiviral.2014.01.012.
«Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea». PLOS Medicine. 13 (3): e1001967. Mars 2016. PMC 4773183 . PMID 26930627. doi:10.1371/journal.pmed.1001967. CS1-vedlikehold: vis-forfattere (link)
Cohen, Jon (26. februar 2015). «Results from encouraging Ebola trial scrutinized». Science. doi:10.1126/science.aaa7912.
«T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections». Antiviral Research. 82 (3): 95–102. Juni 2009. PMC 7127082 . PMID 19428599. doi:10.1016/j.antiviral.2009.02.198. CS1-vedlikehold: vis-forfattere (link)
«Favipiravir (T-705), a novel viral RNA polymerase inhibitor». Antiviral Research. 100 (2): 446–54. November 2013. PMC 3880838 . PMID 24084488. doi:10.1016/j.antiviral.2013.09.015.
«Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever». PLOS Neglected Tropical Diseases. 8 (4): e2790. April 2014. PMC 3983105 . PMID 24722586. doi:10.1371/journal.pntd.0002790.
«Zika Virus: Where Is the Treatment?». Current Treatment Options in Infectious Diseases. 2016. s. 208–211. PMC 4969322 . PMID 27547128. doi:10.1007/s40506-016-0083-7. Manglende eller tom |url= (hjelp)
«Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis». The Journal of Infectious Diseases. 213 (8): 1253–61. April 2016. PMC 4799667 . PMID 26655300. doi:10.1093/infdis/jiv586.
«Human Rabies - Virginia, 2017». MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414. Januar 2019. PMC 6334827 . PMID 30605446. doi:10.15585/mmwr.mm675152a2. CS1-vedlikehold: vis-forfattere (link)

dx.doi.org

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 February doi:10.1038/d41573-020-00016-0

drugs.com

«Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production». Drugs.com (på engelsk). Arkivert fra originalen 28. juli 2020. Besøkt 21. september 2020.

fiercepharma.com

https://www.fiercepharma.com/pharma-asia/japan-s-fujifilm-licenses-flu-drug-api-to-china-s-zhejiang-hisun-pharmaceutical-a-first. Manglende eller tom |tittel= (hjelp)

legemiddelverket.no

Legemiddelverket: Favipiravir som mulig behandling av covid-19, oppdatert 19. september 2020, lest 21. september 2020

livemint.com

https://www.livemint.com/companies/news/covid-19-glenmark-begins-phase-3-of-clinical-trials-on-antiviral-favipiravir-11589263621323.html. Manglende eller tom |tittel= (hjelp)

nih.gov

ncbi.nlm.nih.gov

«Favipiravir, an anti-influenza drug against life-threatening RNA virus infections». Pharmacology & Therapeutics: 107512. Februar 2020. PMC 7102570 . PMID 32097670. doi:10.1016/j.pharmthera.2020.107512.
«The 2014 Ebola virus disease outbreak in West Africa». The Journal of General Virology. 95 (Pt 8): 1619–1624. August 2014. PMID 24795448. doi:10.1099/vir.0.067199-0.
«Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model». Antiviral Research. 105: 17–21. Mai 2014. PMID 24583123. doi:10.1016/j.antiviral.2014.02.014.
«Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model». Antiviral Research. 104: 153–5. April 2014. PMID 24462697. doi:10.1016/j.antiviral.2014.01.012.
«Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea». PLOS Medicine. 13 (3): e1001967. Mars 2016. PMC 4773183 . PMID 26930627. doi:10.1371/journal.pmed.1001967. CS1-vedlikehold: vis-forfattere (link)
«T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections». Antiviral Research. 82 (3): 95–102. Juni 2009. PMC 7127082 . PMID 19428599. doi:10.1016/j.antiviral.2009.02.198. CS1-vedlikehold: vis-forfattere (link)
«Favipiravir (T-705), a novel viral RNA polymerase inhibitor». Antiviral Research. 100 (2): 446–54. November 2013. PMC 3880838 . PMID 24084488. doi:10.1016/j.antiviral.2013.09.015.
«Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever». PLOS Neglected Tropical Diseases. 8 (4): e2790. April 2014. PMC 3983105 . PMID 24722586. doi:10.1371/journal.pntd.0002790.
«Zika Virus: Where Is the Treatment?». Current Treatment Options in Infectious Diseases. 2016. s. 208–211. PMC 4969322 . PMID 27547128. doi:10.1007/s40506-016-0083-7. Manglende eller tom |url= (hjelp)
«Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis». The Journal of Infectious Diseases. 213 (8): 1253–61. April 2016. PMC 4799667 . PMID 26655300. doi:10.1093/infdis/jiv586.
«Human Rabies - Virginia, 2017». MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414. Januar 2019. PMC 6334827 . PMID 30605446. doi:10.15585/mmwr.mm675152a2. CS1-vedlikehold: vis-forfattere (link)

nytimes.com

Fink, Sheri (4. februar 2015). «Ebola Drug Aids Some in a Study in West Africa». The New York Times.

reuters.com

«First French Ebola patient leaves hospital». Reuters. 4. oktober 2016.
Brief –Corrected – Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, 16. februar 2020.

sciencemag.org

Cohen, Jon (26. februar 2015). «Results from encouraging Ebola trial scrutinized». Science. doi:10.1126/science.aaa7912.

tass.ru

«Минздрав одобрил первое в России лекарство от коронавируса» (på russisk).

web.archive.org

«Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production». Drugs.com (på engelsk). Arkivert fra originalen 28. juli 2020. Besøkt 21. september 2020.